Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Purity: ≥98%
Pravastatin sodium (Apotex; CS-514; Pravachol; Pravaselect; Apo-Pravastatin; Mevalotin; Elisor; Lipostat), an approved hypolipidemic drug of the statin class, is an HMG-CoA reductase inhibitor against sterol synthesis with potential anti-hyperlipidemic effects. It inhibits HMG-CoA reductase with an IC50 of 5.6 μM. It is natural product isolated from cultures of Nocardia autotrophica. Pravastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing MHC II on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells.
ln Vitro |
Pravastatin (CS-514), a statin medicine, is used in combination with diet, exercise, and weight loss to decrease cholesterol and prevent cardiovascular disease[1].
|
||
---|---|---|---|
ln Vivo |
|
||
Animal Protocol |
|
||
References |
[1]. McTavish D, et al. Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs. 1991 Jul;42(1):65-89.
|
Molecular Formula |
C23H35O7.NA
|
---|---|
Molecular Weight |
446.51
|
CAS # |
81131-70-6
|
Related CAS # |
Pravastatin;81093-37-0;Pravastatin sodium (Standard);81131-70-6;Pravastatin-13C,d3 sodium
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)[O-])O)O)O.[Na+]
|
Chemical Name |
sodium;(3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoate
|
Synonyms |
Apotex; CS-514 Sodium, Pravachol; Pravaselect; Apo-Pravastatin; Mevalotin; Elisor; Lipostat; Pravastatin Sodium; Aventis; Bristacol; CS 514; CS-514; CS514;
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.60 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.60 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.60 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (223.96 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.2396 mL | 11.1980 mL | 22.3959 mL | |
5 mM | 0.4479 mL | 2.2396 mL | 4.4792 mL | |
10 mM | 0.2240 mL | 1.1198 mL | 2.2396 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT03944512 | Active, not recruiting | Drug: Pravastatin Other: Placebo |
Preeclampsia Obstetric Labor Complications |
The George Washington University Biostatistics Center |
July 17, 2019 | Phase 3 |
NCT01717586 | Active, not recruiting | Drug: Pravastatin Drug: Placebo |
Preeclampsia | The University of Texas Medical Branch, Galveston |
August 2012 | Phase 1 |
NCT01146093 | Completed | Drug: Pravastatin Sodium | Healthy | Dr. Reddy's Laboratories Limited | November 2002 | Phase 1 |
NCT01146106 | Completed | Drug: Pravastatin Sodium | Healthy | Dr. Reddy's Laboratories Limited | December 2002 | Phase 1 |